Tirzepatide
Dual GIP/GLP-1 agonist
Research overview
A dual-acting peptide on the GIP and GLP-1 receptors, the subject of extensive metabolic research.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $375 CAD
- Purity
- ≥99.1% (HPLC)
- Presentation
- 10 mg lyophilized vial
Order / inquire about Tirzepatide
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
Tirzepatide is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Synthetic single-molecule dual co-agonist of the GIP and GLP-1 receptors, built on the GIP backbone, investigated for glycemic control and weight reduction with high single-agent efficacy. A C20 fatty-diacid chain confers once-weekly dosing.
Mechanism of action
Simultaneously activates the GIP and GLP-1 receptors, producing synergistic effects on glucose-dependent insulin secretion and glucagon suppression, plus action on brain regions that regulate appetite. Slows gastric emptying and reduces energy intake.
Research areas
- Glycemic control in type 2 diabetes (SURPASS 1-5)
- Body-weight management / obesity (SURMOUNT)
- Insulin sensitivity and metabolic parameters
Studied effects in research models
- HbA1c reduction of ~1.24 to 2.58%
- Weight reduction of ~5.4 to 11.7 kg (5-15 mg weekly across trial arms)
- No increased risk of hypoglycemia as monotherapy
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
Developed by Eli Lilly and FDA-approved in 2022 (Mounjaro). Engineered to exploit the incretin synergy of GIP and GLP-1 physiology in a single molecule, it demonstrated efficacy exceeding GLP-1 mono-agonists in head-to-head trials (SURPASS-2 vs semaglutide).
Considerations & limitations
Research use only in this context; the approved drug is not authorized by Health Canada as a research reagent. Dose-dependent GI effects; gallbladder/biliary risk linked to rapid weight loss. Rodent thyroid C-cell tumor warning — contraindicated with medullary thyroid carcinoma or MEN2. May reduce oral-contraceptive efficacy via delayed gastric emptying; hypoglycemia risk with insulin/secretagogues. Dual agonism makes correct sequence identity critical — require COA with HPLC/MS, net peptide content, and endotoxin testing.
References
- [1]Frías et al., 2021 (SURPASS-2 vs semaglutide) — N Engl J Med; PMID: 34170647
- [2]Jastreboff et al., 2022 (SURMOUNT-1, obesity) — N Engl J Med; PMID: 35658024
- [3]Coskun et al., 2018 (tirzepatide discovery/pharmacology) — Mol Metab; PMID: 30473097